Latest Oxaliplatin Stories
Exploratory Analysis of Phase 2 Trial Shows Earlier and Sustained Responses in Patients Treated With Vectibix Versus Bevacizumab THOUSAND OAKS, Calif., Jan.
RnRMarketResearch.com adds “Nintedanib (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store.
RnRMarketResearch.com adds “Zaltrap (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store.
Generics Division of Sanofi, Winthrop US, to Market the Drug BRIDGEWATER, N.J., Aug.
The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies.
Study Shows Improved Survival Benefit in Panitumumab Arm THOUSAND OAKS, Calif., May 31, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 2 PEAK study that reinforce
New Data Reinforces Commitment to Personalized Medicine and Highlights Advances in Immunotherapy Platform THOUSAND OAKS, Calif.
Vectibix is the First and Only Biologic to Offer Significant Survival Benefit as a First-Line Treatment with FOLFOX Chemotherapy for Patients with Wild-Type KRAS Metastatic Colorectal Cancer THOUSAND
Taking low doses of aspirin (which inhibits platelet function) after a colon cancer diagnosis appears to be associated with better survival if the tumor cells express HLA class I antigen.
- totally perplexed and mixed up.